| Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review). | |
| | |
MedLine Citation:
|
PMID: 21993838 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Obesity and diabetes once considered 'rich man's diseases' are one of the biggest public health challenges of the 21st century. Obesity being a gateway to diabetes is a global problem. The supporting statistics are alarming since diabetes is reaching pandemic proportion all over the world. Eighty percent of all patients with diabetes live in developing countries. In this review we describe the role of plasminogen activator inhibitor type one (PAI-1) in the pathology of obesity and diabetes and its potential to be a target in therapy. PAI-1 is the fast acting and specific inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), the activators of plasminogen and consequently of fibrinolysis. In obesity and diabetes it has been linked to the increased incidence of thrombosis. However, PAI-1 is also involved in the regulation of other proteins engaged in hemostasis. These molecules include transforming growth factor β (TGF-β), tumor necrosis factor α (TNF-α), angiotensin II and interleukin 6 (IL-6), all of which up-regulate PAI-1 in various cell types or can be up-regulated by PAI-1. Thus, PAI-1 plays a critical role in the insulin resistance syndrome, which leads to type 2 diabetes mellitus, and is associated with its side effects such as an increased risk of diabetic nephropathy, atherosclerotic cardiovascular disease and others. Thus inactivating of PAI-1 or increasing its clearance can alleviate the burden of obesity and diabetes. |
| | |
Authors:
|
Jerzy Jankun; Abdulrahman Al-Senaidy; Ewa Skrzypczak-Jankun |
Related Documents
:
|
21680988 - Linagliptin: a new dpp-4 inhibitor for the treatment of type 2 diabetes mellitus. 918938 - Association between hla-b7 and allergic reactions to insulin in insulin-dependent diabe... 3700028 - Autofluorescence of the lens in diabetic and healthy subjects by fluorophotometry. 1890288 - Choice enhances performance in non-insulin dependent diabetics and controls. 10750628 - Empowering diabetes out-patients with structured education: short-term and long-term ef... 12625478 - Autonomic mechanism and defects in the glucagon response to insulin-induced hypoglycaemia. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-10-11 |
Journal Detail:
|
Title: International journal of molecular medicine Volume: - ISSN: 1791-244X ISO Abbreviation: - Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-10-13 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9810955 Medline TA: Int J Mol Med Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Urology, Urology Research Center, The University of Toledo, Health Science Campus, MS#1091, 3000 Arlington Ave., Toledo, OH 43614, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dissolution of iron oxide nanoparticles inside polymer nanocapsules.
Next Document: [End-of-Life Decisions in Cases of Vegetative State from the Legal Point of View].